Antibodies that selectively bind HDAC9

US7816499B2 · kind B2 · utility

Assignee

• Sloan Kettering Institute for Cancer Research · US

Inventors

• Victoria M. Richon · Wellesley, US
• Xianbo Zhou · Dobbs Ferry, US
• Richard A. Rifkind · New York, US
• Paul A. Marks · Washington, US

Key dates

• Filing date: May 31, 2007
• Grant date: Oct 19, 2010
• Expiry date: Sep 19, 2028

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N9/80
• WIPO field: Biotechnology
• WIPO sector: Chemistry

Abstract

The present invention features, inter alia, purified antibodies that selectively bind an isolated or recombinant histone deacetylase polypeptide comprising the amino acid sequence as set forth in SEQ ID NO: 2, which comprises a histone deacetylase catalytic domain at amino acids 635 to 953 of SEQ ID NO: 2, purified antibodies that selectively bind a biologically active fragment of the polypeptide of SEQ ID NO: 2, which fragment exhibits histone deacetylase activity, transcription repression activity, and the ability to deacetylate cellular substrates, purified antibodies that selectively bind an isolated or recombinant histone deacetylase polypeptide encoded by a nucleotide sequence as set forth in SEQ ID NO: 1, purified antibodies that selectively bind an isolated or recombinant histone deacetylase polypeptide comprising the amino acid sequence as set forth in SEQ ID NO: 2 lacking a nuclear localization signal, and purified antibodies that selectively bind an isolated or recombinant histone deacetylase polypeptide having at least 95% amino acid sequence identity to SEQ ID NO: 2 and which exhibits histone deacetylase activity, transcription repression activity, and the ability to d…